Researchers have presented the first results of a clinical trial investigating whether genetically engineered insulin-producing cells can be transplanted without requiring patients to take lifelong immunosuppressive drugs. The study was presented at the 2026 Annual Meeting of the International Society for Stem Cell Research (ISSCR), according to Medical Xpress.
Today, the standard treatment for type 1 diabetes is lifelong insulin therapy because the body's immune system destroys the pancreatic β-cells that produce insulin. Although transplantation of donor insulin-producing cells has the potential to restore natural insulin production, recipients typically require lifelong immunosuppressive medications to prevent the immune system from rejecting the transplanted cells.
The new research aims to overcome this major challenge. Scientists are using allogeneic (donor-derived) insulin-producing cells that have been genetically engineered to become less visible to the immune system—a strategy known as hypoimmune engineering.
In the first human clinical trial of its kind, researchers are evaluating whether these modified cells can survive long-term, continue producing insulin, and evade immune attack without the need for continuous immune suppression.
According to the study's lead investigator, Dr. Sonja Schrepfer of Cedars-Sinai Medical Center, this is the first opportunity to evaluate such a technology directly in human patients.
If the approach proves successful, it could pave the way for a functional treatment for type 1 diabetes. Patients may eventually regain the ability to produce their own insulin, eliminating not only the need for daily insulin injections but also the lifelong use of immunosuppressive drugs, which increase the risk of infections and other serious complications.
The researchers caution that many important questions remain unanswered. Future studies will need to determine how long the transplanted cells can survive and function, how they interact with the immune system over time, and whether the technology can be developed into a widely available treatment.
According to the authors, the implications of this strategy could extend well beyond diabetes. If transplanted cells can be reliably protected from immune rejection, the same technology could eventually enable the development of off-the-shelf cell, tissue, and even organ transplants for the treatment of a wide range of diseases.
Follow NEWS.am Medicine on Facebook and Twitter